Background The discovery of somatostatin (SST) and the synthesis of a variety of analogues
constituted a major therapeutic advance in the treatment of gastroenteropancreatic …

Endocrine pancreatic tumours (EPTs) are uncommon tumours occurring in approximately 1
in 100 000 of the population, representing 1–2% of all pancreatic neoplasms. Some of the …

Purpose: Somatostatin analogs and interferon alfa control hormone-active/functional
neuroendocrine gastroenteropancreatic tumors. In addition to hormonal control, variable …

Gastroenteropancreatic neuroendocrine tumours (GEP NETs) are rare tumours that present
many clinical features. They secrete peptides and neuroamines that cause distinct clinical …

Since the discovery of somatostatin (sst) in 1973, numerous chemical and biological studies
have been carried out to develop sst analogs with enhanced resistance to proteases and …

Neuroendocrine gastrointestinal tumors express somatostatin receptors (ssts) in 80%–90%
of cases and somatostatin analogs have become increasingly important in the management …

Although recent epidemiological evidence indicates that the prevalence of non-functioning
gastroenteropancreatic (GEP) neuroendocrine tumours (NETs) is rising, a significant …

Background. For decades, somatostatin analogs (including octreotide and lanreotide) have
been indicated for relief of the symptoms of flushing, diarrhea, and wheezing associated with …

Gastroenteropancreatic neuroendocrine tumors (GEP-NETs) are rare tumors that present
many clinical features secreting peptides and neuroamines that cause distinct clinical …

Background Somatostatin (SST) analogues represent a novel approach for the treatment of
certain cancers. The objective of this article is to summarise the current knowledge on SST …